China BCI Ecosystem
The China BCI ecosystem matured rapidly in 2024–2026. Neuracle × Tsinghua received NMPA approval in 2026-03, becoming the world's first commercialized implantable BCI. Together with StairMed, NeuraMatrix, Neuracle (Bo Rui Kang) and others, China's BCI sector has formed a bipolar global structure independent of the United States.
1. Policy Backdrop
2023: "BCI Listed as a 14th Five-Year Plan Emerging Industry"
- State Council planning
- National funding + local subsidies
- Ministry of Education approved a BCI major
2024 Regulatory Framework
- NMPA (National Medical Products Administration) dedicated BCI guidance
- Green channel (similar to FDA Breakthrough)
- Data Security Law + Biosecurity Law
2025–2026 Local Policy
- Shanghai: Zhangjiang Medical Robotics Center
- Beijing: Brain Science and Brain-Like Research Center
- Shenzhen: industrialization support
2. Neuracle (Bo Rui Kang Medical) × Tsinghua
Tsinghua BCI Lab
- Led by Hong Bo (Tsinghua Medical School)
- ECoG + invasive research since the 2010s
- NEO (Neural Electronic Opportunity) project
Neuracle Hardware
- NEO wireless BCI
- Epidural electrodes (semi-invasive)
- Wireless power + data
- Down to 64 wireless channels
Clinical Trials
- First patient in 2023 (Xuanwu Hospital)
- Expanded to 5+ patients in 2024
- Quadriplegic patients regaining grasp
2026-03: NMPA Approval
- World's first commercialized implantable BCI
- Milestone for Chinese BCI leadership
- Indication: spinal cord injury
3. StairMed (Jie Ti Yi Liao)
Company
- From Shanghai Jiao Tong and Fudan University lineage
- Founded in 2021
- Funding ~RMB 200 million
Product
- Invasive BCI (flexible electrodes)
- 256+ channels
- Aimed at language restoration
2024 Progress
- First ALS patient implanted
- Speech-decoding task
- NMPA submission expected 2026
4. NeuraMatrix
Company
- Spin-out from Tsinghua Tianjin
- Founded in 2019
- Focus on brain organoids + BCI
Product
- High-density Utah-like array
- 1024 channels
- Long-term stability research
Positioning
- Research-oriented
- Many academic collaborations
- Slower commercialization path
5. Other Participants
NeuroXess
- Focus on DBS + BCI integration
- Parkinson's + motor control
Shanghai Jiao Tong University School of Medicine
- Qian Xiaodong's group
- Visual prosthesis research
- Collaboration with Fernández
Fudan Institutes of Brain Science
- Brain-inspired computing + BCI
- "Brain-machine fusion" direction
Huazhong University of Science and Technology
- EEG / non-invasive BCI
- Consumer-grade exploration
6. Consumer EEG
BrainCo
- Incubated at Harvard
- Dual China/US headquarters
- Consumer-grade EEG headband
Products
- Focus: attention training
- OxyZen: relaxation
- Prosthetics: EMG + EEG hybrid
Controversy
- Schools using it to monitor student attention
- Privacy + ethics controversy
- Media criticism in 2023
NeuraLynx and Others
- EEG monitoring devices
- Hospital diagnostics
7. Research Directions
1. Semantic Decoding (Tang-style)
- Joint work by Peking University, Tsinghua, CAS
- Mandarin semantic reconstruction research
2. Visual Prosthesis
- SJTU, Zhejiang University
- Collaboration with CAS
3. Motor BCI
- Tsinghua, Fudan
- Benchmarked against BrainGate
4. Brain-Spinal Bridge (Courtine-style)
- Shanghai Ruijin Hospital
- 2025 prototype
8. Data and Algorithms
Domestic Neural Foundation Models
- LaBraM (PKU): EEG foundation model
- SEED dataset (SJTU): affective EEG
- BCI Competition China
Integration with Domestic LLMs
- Qwen, DeepSeek as BCI back ends
- Analogous to Synchron × OpenAI but local
- Guarantees data sovereignty
9. Differences from the United States
Regulation
- NMPA vs FDA
- Chinese approval may be faster (for domestic products)
- International recognition is lower
R&D
- Tight academia-industry coupling
- Strong government funding
- Top talent partly drawn from returning expatriates
Market
- 1.4 billion population with potential patient base
- Insurance coverage still evolving
- High consumer acceptance
Collaboration Model
- U.S./Europe: company + academia + FDA
- China: universities + state-owned firms + government
10. International Cooperation and Competition
Cooperation
- Neuralink previously visited Tsinghua
- Frequent academic exchange (before 2022)
- Post-2023 geopolitical tensions have cooled this
Competition
- Who commercializes first = Neuralink vs Neuracle
- China was one step ahead in 2026-03
Export Controls
- BCI chips may be affected
- Some high-end electrode materials restricted
- But domestic self-sufficiency is rising
11. Outlook 2026–2030
Projections
- 2026–2027: 5–10 Chinese BCI companies expand financing
- 2027: 2–3 receive NMPA approval and commercialize
- 2028: consumer EEG at scale
- 2030: the Chinese BCI market rivals the U.S.
Risks
- Policy changes
- Contraction of international scientific collaboration
- Ethical concerns (over-rapid commercialization)
Opportunities
- Massive patient population
- Government support
- Domestic AI + BCI integration
12. Logic Chain
- Policy + national strategy drove the Chinese BCI boom from 2023 onward.
- Neuracle × Tsinghua 2026-03 NMPA approval is the world's first commercialized implantable BCI.
- StairMed, NeuraMatrix, NeuroXess, BrainCo form a diversified company ecosystem.
- Research spans semantic decoding, visual prostheses, motor BCI, and brain-spinal bridges.
- Domestic foundation models + domestic LLMs close the data-sovereignty loop.
- A bipolar landscape: Chinese regulation and markets are independent, but talent and collaborations remain international.
- 2026–2030 is the key window for Chinese BCI marketization and international export.
References
- Wang et al. (2024). NEO: A wireless electrocorticographic neural interface for severe motor impairment. Nat Biomed Eng. — Neuracle × Tsinghua
- Hong Bo Lab (2024). NEO technical white paper. thu.edu.cn
- NMPA (2026). BCI device approval announcement.
- China BCI Industry Alliance (2024). White paper.
- Cuntai Guan et al. (multiple reviews). Asian BCI progress.